Major collaboration in cancer treatments inspired by marine organisms

Eczacıbaşı Group Chairman Bülent Eczacıbaşı and PharmaMar Chairman José María Fernández Sousa

Eczacıbaşı Pharmaceuticals Marketing has signed a licensing agreement with PharmaMar, the world leader in the discovery of antitumor drugs of marine origin. The agreement with PharmaMar, which has its headquarters in Madrid, will begin with plitidepsin, a new therapy for several types of melanoma.
 
PharmaMar Chairman José María Fernández Sousa, Eczacıbaşı Group Chairman Bülent Eczacıbaşı, Eczacıbaşı Group Vice Chairman Faruk Eczacıbaşı, Eczacıbaşı Group CEO Atalay Gümrah, and Eczacıbaşı Group Executive Vice President of Healthcare Elif Çelik were present at the official signing of the agreement, which took place at the Eczacıbaşı Group’s headquarters at Kanyon.
 
In his speech at the ceremony, Bülent Eczacıbaşı stressed the critical importance of new collaborations in healthcare that create innovation and add value and continued, “In this sense, PharmaMar is undoubtedly the most fitting partner.” José María Fernández Sousa underlined PharmaMar’s commitment to the development of innovative oncology therapies and said, “We can’t wait to begin cooperating with one of the oldest and most prominent pharmaceutical companies in Turkey.”


Left to right – PharmaMar Business Development and Licensing Director Christophe Chevreau, Eczacıbaşı Group Executive Vice President of Healthcare Elif Çelik, PharmaMar Executive Vice President of Business Development Heiner Pieper,  Eczacıbaşı Group Chairman Bülent Eczacıbaşı, PharmaMar Chairman José María Fernández Sousa, Eczacıbaşı Group Vice Chairman Faruk Eczacıbaşı, Eczacıbaşı Group CEO Atalay Gümrah

About PharmaMar
 
Based in Madrid, PharmaMar is the world leader in the discovery and development of marine-based innovative drugs to fight cancer. Acclaimed for its major development projects and powerful R&D program in the field of oncology, PharmaMar has one drug that is already used in Europe to treat a variety of cancers and three more drugs under development. PharmaMar has subsidiaries and affiliates in Germany, Italy, France, Switzerland, the UK, Belgium, Austria and the US, among them Genomica, the leader in Spain in the discovery of molecules, and Sylentis, a biotech company involved in the research and development of applications for RNA interference (RNAi) therapies.